Free Trial

Enliven Therapeutics (ELVN) Stock Forecast & Price Target

$22.01
-0.59 (-2.61%)
(As of 07/19/2024 08:55 PM ET)

Enliven Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 3 Wall Street analysts who have issued ratings for Enliven Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 2 have given a buy rating, and 1 has given a strong buy rating for ELVN.

Consensus Price Target

$33.00
49.93% Upside
High Forecast$34.00
Average Forecast$33.00
Low Forecast$32.00

According to the 3 analysts' twelve-month price targets for Enliven Therapeutics, the average price target is $33.00. The highest price target for ELVN is $34.00, while the lowest price target for ELVN is $32.00. The average price target represents a forecasted upside of 49.93% from the current price of $22.01.

TypeCurrent Forecast
7/23/23 to 7/22/24
1 Month Ago
6/23/23 to 6/22/24
3 Months Ago
4/24/23 to 4/23/24
1 Year Ago
7/23/22 to 7/23/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$33.00$33.00$34.00$27.00
Forecasted Upside49.93% Upside61.45% Upside85.79% Upside14.94% Upside
Get Enliven Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter.

ELVN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ELVN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Enliven Therapeutics Stock vs. The Competition

TypeEnliven TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.33
2.72
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside49.93% Upside2,980.95% Upside10.08% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/11/2024Baird R W
0 of 5 stars
C. Kusy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/11/2024Robert W. Baird
2 of 5 stars
 Initiated CoverageOutperform$32.00+41.72%
4/9/2024Mizuho
2 of 5 stars
 Initiated CoverageBuy$34.00+85.79%
3/29/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$27.00+14.94%
3/7/2023Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Slutsky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
3/3/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:51 AM ET.

ELVN Forecast - Frequently Asked Questions

What is Enliven Therapeutics' forecast for 2024?

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Enliven Therapeutics is $33.00, with a high forecast of $34.00 and a low forecast of $32.00.

Should I buy or sell Enliven Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enliven Therapeutics in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ELVN shares.

Does Enliven Therapeutics's stock price have much upside?

According to analysts, Enliven Therapeutics's stock has a predicted upside of 61.45% based on their 12-month stock forecasts.

Has Enliven Therapeutics been upgraded by Wall Street analysts recently?

Over the previous 90 days, Enliven Therapeutics's stock had 1 upgrade by analysts.

What analysts cover Enliven Therapeutics?

Enliven Therapeutics has been rated by research analysts at Baird R W, and Robert W. Baird in the past 90 days.

Do Wall Street analysts like Enliven Therapeutics more than its competitors?

Analysts like Enliven Therapeutics more than other "medical" companies. The consensus rating for Enliven Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ELVN compares to other companies.


This page (NASDAQ:ELVN) was last updated on 7/22/2024 by MarketBeat.com Staff

From Our Partners